The CBSE Class 12 Mathematics board exam 2026 was conducted on March 9 from 10:30 am to 1:30 pm at centres across the country. The paper is considered crucial for students from science and commerce ...

The board added that a separate notification will be issued outlining how results will be declared for affected students.

CBSE Board 2026 Physics Exam Highlights: The Central Board of Secondary Education (CBSE) conducted examinations for Classes 10 and 12 on the fourth day on Friday. The exams for Class 10 papers, Beauty ...

HYDERABAD: Indicating that his government was working for a healthy, secure and bright future for citizens, Chief Minister A Revanth Reddy on Thursday said the ...

Students should focus on GDP, demand–supply diagrams, fiscal policy, and previous year questions to improve scores in the Economics board exam.

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

The stock of Structure Therapeutics rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug. The stock rose 8% to $58.07 in premarket trading ...

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

BYDFi announced the integration of its perpetual futures market data into TradingView, enabling traders to access real-time pricing and crypto market signals directly within TradingView charts. The ...

The $10 billion need is structured as a project-collateralized facility, each phase backed by its assets, contracts, and revenue. This approach matches current funding practices. Reliable electricity ...

Structure Therapeutics said on Monday its pill helped patients lose up to 16.3% of their weight, strengthening its bid to challenge Eli Lilly ​and Novo Nordisk in the increasingly competitive race ...